Manufacturing News of Note—Lonza expands cell therapy facility; Mylan recalls anxiety drug

stocks
(PIxabay)

> Mylan is voluntarily recalling more than 10,000 bottles of generic Xanax, saying there is a small risk from a foreign substance. Release

> Lonza says it will expand its Singapore cell therapy operation and use new technology to produce commercial-scale product of an allogeneic cell treatment being developed by Mesoblast the biotech expects to submit to the FDA for review by the end of the year. Release

> The FDA has posted a warning letter to Glenmark that the Indian drugmaker earlier this month reported it had received. Warning letter

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

> U.K.-based CDMO Sterling Pharma is investing $1.5 million in a plant in Research Triangle Park, North Carolina, that it acquired earlier this year. 

> China’s API maker WuXi Sta say its manufacturing facility in Jinshan in Shanghai has passed a European Medicines Agency inspection. Release 

> There have been shortages in hormone replacement therapy in the U.K. Release 

> CPI and Strathclyde University, in a partnership with GlaxoSmithKline and AstraZeneca, have begun work on a continuous direct compression platform for oral solid dose meds. Story 

> India's Lupin, which has a long list of FDA manufacturing issues, says its plant in Nagpur passed an inspection with no observations. Release

> Taiwanese CDMO Bora, which specializes in complex modified release products, has opened a U.S. office in Delaware. Release

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Gilead Sciences will donate 1.5 million doses of COVID-19 hopeful remdesivir as its manufacturing of the drug hits light speed.

Sanofi, a hydroxychloroquine maker, is producing as much as it can amid the pandemic, but some workers are having to exit the line manufacturing line.